spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

New research calls for pathology services to be better funded and prioritised

MindMetre Research

Research report from MindMetre presents evidence of the high value offered by pathology services, and suggests that current efficiency savings plans be reviewed

A new report from independent research organisation MindMetre has summarised the evidence for return-on-investment from pathology services in the NHS and questioned any urgent pressure to consolidate pathology laboratories - within and between NHS trusts.

The MindMetre report, which reviewed the range of existing evidence and also canvassed views among a sample of 30 laboratory managers and principal biochemists in England and Wales, was conducted in response Lord Carter’s latest report, Operational productivity and performance in English NHS acute hospitals: Unwarranted variations (February 2016).

The Carter report notes that, “If benchmarks for pathology are unlikely to be achieved [by the deadline of April 2017], trusts should have agreed plans for consolidation and outsourcing to, other providers by January 2017.” The MindMetre review and research cautions against such a tight deadline being imposed, arguing that merger planning is not a substitute for within-laboratory efficiency and improvement drives.

The MindMetre review suggests that a mandatory pathway is set for laboratory productivity improvement (particularly turnaround time reduction), recognising that all aspects of the NHS have to deliver efficiency savings in the current policy environment. However, the review also suggests that the high value offered by pathology services be re-appraised at the strategic level to determine their position in the NHS service funding priorities.

Evidence covered in the review suggests that the immediate and knock-on effects of pathology service capacity and efficiency/productivity are more considerable than service funding would suggest, and could make an even more disproportionately positive contribution to patient outcomes, rapid diagnosis and the avoidance of unnecessary interventions and chronic condition development further down the line.

Paul Lindsell, Mind Metre Managing Director, comments: “A knee-jerk push to consolidate pathology labs is not an easy universal panacea. There is evidently significant headroom for efficiency and productivity gains in pathology workflows and emerging technology. Our report recognises frustrations that greater productivity gains have not yet been achieved. However, we also suggest that the through-the-line benefits that pathology services offer mean it would be a mistake to potentially squeeze such resources in the NHS. In fact, there may be a rationale to put greater resources into pathology services, so long as they are strictly pegged to productivity improvements.”
email info@mindmetre.com
web www.mindmetreresearch.com/
 
Print this page
Send to a friend
   
spacer
News and Press Releases

PCI Pharma Services Announces Serialization Installation at Tredegar Manufacturing Center of Excellence

PCI Pharma Services (PCI) is pleased to announce the installation and validation of its latest comprehensive Serialization system, located at its manufacturing Center of Excellence in Tredegar, UK.  The investment demonstrates PCI’s continued investment in and expansion of market-leading Serialization capabilities. This latest installation increases PCI’s Serialization capability to support clients in advance of implementation dates for the European Falsified Medicines Directive (EU FMD), as well as supply for the US and emerging markets, including countries such as China, Turkey, Brazil, Saudi Arabia and others.  PCI’s system is compliant to all EU member country requirements for Serialization and specialized labeling, including application and integration of advanced Anticounterfeiting technologies.
More info >>


White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>

Industry Events

BioPharm America 2018

5-6 September 2018, Hynes Convention Center

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement